Recent Molecular Assessment of Plasmodium vivax and Plasmodium falciparum Asymptomatic Infections in Botswana

Thato Motshogoe,1,2 Daniel H. Haiyambo,3,4 Ruth Ayanfu-Torgby,5 Larysa Aleksenko,6 Davies Ntebela,7,8 Benoit Malleret,9 Laurent Rénia,10 Elias Peloewetse,10,11,12 Giacomo Maria Paganotti,13 and Isaac K. Quaye14

1University of Botswana, Department of Biological Science, Gaborone, Botswana; 2University of Namibia School of Medicine, Windhoek, Namibia; 3Regent University College of Science and Technology, Department of Engineering, Computing and Allied Health Sciences, Accra, Ghana; 4Biomedical and Public Health Research Unit, Council for Scientific and Industrial Research–Water Research Institute, Council Close, Accra, Ghana; 5University of Lund, Department Clinical Sciences, Lund, Sweden; 6National Malaria Program Ministry of Health and Wellness, Gaborone, Botswana; 7Department of Microbiology and Immunology, Immunology Translational Research Program, Yong Loo Lin School of Medicine, Immunology Program, Life Sciences Institute, National University of Singapore, Singapore; 8Singapore Immunology Network (SIgN), Agency for Science, Technology and Research (A∗STAR), Biopolis, Singapore; 9A∗STAR Infectious Diseases Laboratories, Agency for Science, Technology and Research (A∗STAR), Biopolis, Singapore; 10Botswana–University of Pennsylvania Partnership, University of Botswana, Gaborone, Botswana; 11Division of Infectious Diseases, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania; 12Department of Biomedical Sciences, Faculty of Medicine, University of Botswana, Gaborone, Botswana

Abstract. In 2016, we reported the presence of Plasmodium vivax in Botswana through active case detection. A real-time PCR was used during a similar study in 10 districts to assess changes in the P. vivax prevalence. We assessed 1,614 children (2–13 years of age) for hemoglobin (Hb; g/dL) and Plasmodium parasites. The median age of all participants was 5.0 years (25th percentile, 3 years; 75th percentile, 8 years). The median Hb (g/dL) level was 12.1, but 18.3% of the participants had anemia (Hb < 11.0 g/dL); these participants were clustered in the younger than 5 years age group in all districts (P < 0.001). The risk of anemia decreased with age 5 years or older (odds ratio [OR], 0.26; 95% confidence interval [CI], 0.197–0.34; P < 0.001). The risk of anemia in children decreased with age 5 years or older (odds ratio [OR], 0.26; 95% confidence interval [CI], 0.197–0.34; P < 0.001). The prevalence rates of Plasmodium parasites were as follows: P. vivax, 12.7%; P. falciparum, 12.7%; P. malariae, 0.74%; and P. ovale (P. ovale curtisi), 0.68%. Mixed infection rates were as follows: P. falciparum and P. vivax, 2.35%; P. falciparum and P. ovale curtisi, 0.56%; P. vivax and P. malariae, 0.06%; and P. falciparum and P. malariae, 0.68%. The infections were largely asymptomatic (99.6%). Using logistic regression, the risk of infection with P. vivax was highest in Kweneng East (OR, 6.2; 95% CI, 2.9–13.1), followed by South East (OR, 5.6; 95% CI, 2.5–12.3) and Ngami (OR, 5.1; 95% CI, 2.2–12.0). Compared to the risk of infection for children younger than 5 years, the risk of infection decreased for children 5 years or older in regions with high rates of P. vivax and P. falciparum infections. P. vivax and P. falciparum have expanded within the asymptomatic population in Botswana; therefore, careful attention is required for their elimination.

INTRODUCTION

Botswana is a member of the Southern African Development Community (SADC) Elimination 8 (E8) countries that aimed to eliminate malaria by 2018.1 Unfortunately, the elimination target could not be achieved because of persistent factors, including the sole focus of the National Malaria Program (NMP) on Plasmodium falciparum (P. falciparum) for elimination, limited human resource capacity, and structural/logistic impediments that affect disease surveillance.

In 2016, the first report of the presence of asymptomatic P. vivax infections in the country was made in a collaborative venture with the NMP.2 Between 2015 and 2017, a similar collaboration to perform active case detection of all Plasmodium species that infect humans (P. falciparum, P. vivax, P. ovale) and P. malariae in schools and hospitals located in 10 districts across the country was performed to assist the NMP with the stratified data required for an effective malaria elimination plan.3–5 In 2019, the World Health Organization (WHO) noted that the elimination agenda in Botswana was not working and needed to be reviewed with a new approach.6 This was a necessary approach to align with the overall global target of malaria eradication.7

It has been well-established that as the rates of malaria attributable to P. falciparum decrease, the rates of non-falciparum (P. vivax, P. ovale, and P. malariae) malaria increase.8,9 In addition, P. vivax is now well-recognized in Africa, including in Duffy-negative individuals.10 Both P. malariae and P. ovale are commonly found in Africa. However, unlike the two sympatric species of P. ovale (P. ovale wallikeri and P. ovale curtisi) that have hypnozoites stages similarly to P. vivax, it is unknown if P. malariae have hypnozoites even though they have long latency periods and can sustain infections through relapses or recrudescences.11,12 P. malariae is known to have an enhanced capability to sustained infection in humans.13 Several reports have shown that asymptomatic infections with all Plasmodium species comprise a significant portion of the burden of disease.11,14,15 Therefore, it is reasonable to surmise that a more effective approach to malaria elimination and eradication in Africa should consider a strategy that targets all Plasmodium species in parallel in asymptomatic and symptomatic infections based on accurate active case detection using highly sensitive molecular tools.16 It is essential for the scientific community to work closely with National Malaria Control Programs (NMCPs) to achieve this goal. By obtaining data regarding all Plasmodium species in Africa, the impetus for guidance regarding the elimination and eradication strategies will allow NMCPs to retool their resources appropriately.17

There are geospatial limits to the transmission dynamics of Plasmodium species that can be missed with passive data collection, which is unable to detect submicroscopic and
asymptomatic infections and how they contribute to transmission. The Botswana NMP is retooling to forge a collaboration to create elimination strategies and improve disease surveillance, monitoring, and evaluation. The collaboration will improve the human resources and technical capacity through joint activities with universities and research institutions. We report the data obtained using molecular tools through our close collaboration with the NMP of Botswana to detect active cases of the four *Plasmodium* species that are infectious to humans. We affirm the presence of *P. vivax* and nonfalciparum parasites in Botswana and the changed burden of *P. falciparum* in the country since the 2016 report.

**MATERIALS AND METHODS**

**Study sites and population selection.** The study sites were selected with the support of the NMP of the Ministry of Health and Wellness (MOHW) and Ministry of Education of Botswana, as reported previously. The sites were Okavango, Ngami, Chobe, Tutume, Francistown, Palapye, Serowe, Kweneng West, Kweneng East, and South East. We used a multistage sampling process to select the schools, clinics/health posts, and participants. The Ministry of Basic Education primary school registers and MOHW clinic/health post registries within each district were used to select the schools and clinics involved in the study enrollment. Briefly, during the first stage, districts with known malaria transmission profiles based on the recommendations of the NMP were selected. During the second stage, towns within the district with variable malaria incidence rates were also selected to ensure heterogeneity within the districts. During the third stage, schools and clinics within each town/village were selected using a two-stage clustering approach based on the population density and adequate cross-sectional representation of the communities to avoid any bias. During the final stage, participants were assigned numbers and enrolled after obtaining informed parental consent and consent from the heads of schools and clinics/health posts. The total number of samples derived for each district/town was in direct proportion to the estimated population density. We enrolled 1,645 children 2 to 13 years of age between December 2015 and February 2017.

**Ethical statement.** The study was approved by the MOHW Ethical Committee of Botswana and the Institutional Review Board of the University of Botswana (permit no. UBR/RES/IRB/BIO/062). All parents/guardians provided informed consent on behalf of all participants. When necessary, assent was also obtained from the child before a sample was collected.

**Sample size.** The sample size was calculated as previously described.

**Selection of subjects.** Community mobilization was performed at Kgota meetings (community meetings with elders of the community), clinics/health posts, and parent–teacher association meetings before enrollment. Children 5 to 9 years of age were enrolled from primary schools. Children 2 to 4 years of age and 10 to 13 years of age were enrolled from the child welfare clinics. Participants were enrolled only if they had no self-reported clinical symptoms.

Written informed consent for participation in the study was obtained in Setswana or English from parents or guardians for each prospective participant before enrollment. Emphasis was placed on the fact that the participants were free to participate or decline participation without any effect on their medical care.

**Blood sample collection and baseline demographics.** Venous blood samples (1.0–1.5 mL) were collected into EDTA tubes. Hemoglobin concentrations (g/dL) were checked immediately using a Hemocue 201 device (Angelholm, Sweden), and the results were provided to the participants’ caregivers. Participants found to have moderate or severe anemia were referred for further investigation and treatment. Fever was defined as a tympanic temperature ≥ 37.8°C at the time of sample collection; asymptomatic participants were those without fever (tympanic temperature < 37.8°C) and without a history of fever during the preceding 72 hours. Sample collections were timed to include the onset and peak of the malaria transmission season.

The samples were transported in cooler boxes within 3 hours of collection to the district hospital. Blood was separated by centrifugation at 5,000 rpm for 5 minutes into plasma and cell pellets. These were stored at −80°C until they were analyzed.

Demographic variables that were recorded at the time of blood sample collection were age, sex, ethnicity, height, weight, tympanic temperature, place of residence, travel history, and malaria diagnosis during the previous year. Participants who were underweight were referred for further management. Participants who were febrile were also referred to the outpatient department for further management.

**Laboratory analysis.** DNA extraction. Genomic DNA was extracted from the pellet cells and purified using the Hamilton Star Microlab WorkStation (Hamilton Bonaduz AG, Bonaduz, Switzerland) robotic system. The instructions accompanying the Machery and Nagel (MN) Nucleospin 96 blood kit were followed to achieve the extraction of high-quality DNA. This method uses silica membrane technology for binding DNA after lysis to facilitate purification. The starting blood sample was 200 μL of the packed and thawed erythrocytes, and final DNA elution volume was 120 μL sterile PCR-grade water. Then, 5 μL of the extracted DNA was used for nested PCR and 2.5 μL was used for quantitative PCR (qPCR).

**Molecular detection of Plasmodium species.** All *Plasmodium* species were detected by modification of the double-nested PCR procedure targeting conserved species–specific regions of the 18S small subunit of ribosomal RNA (18S ssRNA) as previously reported. For qPCR, the genus-specific primers and probes were those that have been previously described. The species-specific primers and probes for *P. falciparum*, *P. vivax*, *P. ovale*, and *P. malariae* were also published previously. Samples were screened during the qPCR for positivity and affirmed for species using nested PCR. All nested detection assays were single-plex and performed in a high-throughput 96-well plate (ABI GeneAmp 9700 PCR system; Applied BioSystems, Singapore), and the CFX96 Real-Time PCR detection system (Bio-Rad Laboratories, Pretoria, South Africa) was used for all qPCR assays. The kits used for nested PCR were the Qiagen PCR core kit (Qiagen, Valencia, CA); the KAPA PROBE FAST qPCR Master Mix (2X) (Sigma Inc., Cape Town, South Africa) or the abTBS Malaria 5 qPCR II Kit (AlTBiotech Pte Ltd, Singapore) were also used for PCR. Species-specific primers and probes were ordered from Eurogentec (Liege, Belgium). Standard controls of *Plasmodium* species 3D7 synchronized cultured parasites were obtained by cell sorting flow cytometry as described previously (10,000 rings in 50 μL of packed red blood cells). Details of the amplification reactions and
cycling parameters for qPCR and nested PCR have been published previously.25

Statistical analysis. Data were entered in an Excel (Microsoft, Redmond, WA) data sheet. SPSS version 26 (release 2019; IBM Corp., Armonk, NY) was used for analysis. Descriptive statistics and appropriate measures of central tendency were provided for relevant demographic covariates. To describe differences between study sub-populations (e.g., different regions of residence with respect to the presence/absence of Plasmodium infection, anemia, and/or age), continuous covariates grouped into categories were compared using binary and multinomial logistic regression. Odds ratios (ORs) were used for logistic regression analyses, and 95% confidence intervals (CIs) were used for point estimates. Anemia was defined as hemoglobin < 11.0 g/dL. Statistical significance for all comparisons was set at \( P < 0.05 \). Adjustment was not performed for multiple comparisons during this exploratory study.

RESULTS

Study population. A total of 1,645 children from 10 districts (Figure 1) were enrolled in the study. Data of 1,614 participants were available for analyses (Table 1). The median age of the participants was 5 years (25th percentile, 3 years; 75th percentile, 8 years). Participants from Tutume (median age, 3 years; 25th percentile, 2 years; 75th percentile, 5 years) were the youngest, followed by those from Kweneng East (median age, 5 years; 25th percentile, 3 years; 75th percentile, 8 years; \( P = 0.005 \)) and Serowe (median age, 4 years; 25th percentile, 3 years; 75th percentile, 7 years; \( P = 0.005 \)). Participants from Ngami (median age, 7 years; 25th percentile, 5 years; 75th percentile, 8 years) and Francistown (median age, 7 years; 25th percentile, 4 years; 75th percentile, 8 years) were older than the other participants (\( P = 0.004 \)). The overall median hemoglobin concentration was 12.1 g/dL; however, anemia was present in the < 20th percentile age group in all districts (\( P < 0.001 \)) (Table 1). Of the patients 2 to 11 years of age (median age, 3.2 years; mean age, 3.95 years), 18.3% had anemia. The risk of anemia decreased with age 5 years or older (OR, 0.26; 95% CI, 0.197–0.34; \( P < 0.001 \)). Anemia was significantly related to the district of residence (\( P < 0.001 \)) (Table 1). Tutume (4.5%) had the most cases of anemia (10th percentile, 10.5 g/dL; 25th percentile, 10.5 g/dL; \( P < 0.001 \)), followed by Okavango (\( P = 0.09 \)) and Francistown (\( P = 0.06 \)) (Table 1).). The 10th percentile and 25th percentile hemoglobin concentrations (g/dL), respectively, were 10.2 and 10.7 for Francistown, 10.1 and 11.1 for Chobe, 10.6 and 11.3 for South East, 10.3 and 11.3 for Ngami, 10.5 and 11.4 for Kweneng East, and 10.8 and 11.3 for Serowe. Asymptomatic participants comprised 99.6% of the study population; 0.4% of the symptomatic participants had \( P. falciparum \) and were clustered mainly in Chobe. There was no difference in the sexes of participants who had \( P. falcium \) infections and those who did not.

Plasmodium species. Data regarding \( P. falciparum \) infections were available for 1,614 participants (Table 2). All four \( P. falciparum \) species infectious to humans were observed. The \( P. falciparum \) parasite infections with \( P. falciparum \) (12.7%) and \( P. vivax \) (12.7%) were similar, although the prevalence differed between districts (Table 2). The districts with the highest burden of \( P. falciparum \) infections were Kweneng East (11.96%), South East (5.82%), Ngami (2.6%), Tutume (2.5%), and Palapye (2.5%); Kweneng West (0.80) and Okavango (0.86%) had the least number of \( P. falciparum \) infections. All \( P. falciparum \) infections were present as coinfections with \( P. falciparum \) or \( P. vivax \) and clustered in Kweneng East, South East, Tutume, and Palapye. \( P. vivax \) infections were strongly clustered in Kweneng East (5.6%), South East (2.5%), Ngami (1.3%), and Tutume (0.80%). According to a logistic regression analysis, the three districts with the highest risk of infection with \( P. vivax \) were Kweneng East (OR, 6.2; 95% CI, 2.94–13.1; \( P < 0.001 \)), South East (OR, 5.6; 95% CI, 2.5–12.3; \( P < 0.001 \)), and Ngami (OR, 5.1; 95% CI, 2.2–12.0; \( P < 0.001 \)). There was also a relatively small cluster at increased risk for infection in Kweneng West (OR, 2.7; 95% CI, 0.8–8.7) and Palapye (2.5; 95% CI, 0.9–6.8). The risk of infection with \( P. falciparum \) decreased with age (Figure 1) and was increased in Kweneng West (OR, 0.28; 95% CI, 0.15–0.52; \( P < 0.001 \)), South East (OR, 0.31; 95% CI, 0.16–0.61; \( P = 0.001 \)), and Ngami (OR, 0.35; 95% CI, 0.17–0.74; \( P = 0.006 \)). In contrast, all districts were significantly at risk for infection with \( P. falciparum \) (\( P < 0.001 \)); however, participants 5 years or older were at increased risk for infection in all regions except Chobe and Francistown. Interestingly, participants 5 years or older from Okavango were at increased risk for infection (OR, 2.5; 95% CI, −0.94 to 6.7; \( P = 0.066 \)).

DISCUSSION

The results of our survey demonstrate that the prevalence of asymptomatic \( P. falciparum \) and \( P. vivax \) increased significantly during 2016 to 2017, with \( P. vivax \) accounting for a significant proportion of the asymptomatic \( P. falciparum \) parasite population in Botswana. Interestingly, this observation

| Table 1 | Demographics of participants by district of residence |
|---------|-----------------------------------------------------|
| District/Population | Age, median (25th–75th percentile) | Sex (%) | Hemoglobin, g/dL, median (25th–75th percentile) | Total with anemia, % | Total younger than 5 years, % |
|          | F | M |          |                                      |                  |
| Okavango (194) | 6.0 (4–8) | 11.9 | 12.2 | 12.3 (11.5–13.1) | 1.4 | 3.8 |
| Ngami (116) | 7.0 (5–8) | 6.1 | 8.4 | 12.0 (11.3–12.7) | 1.5 | 1.6 |
| Chobe (162) | 4.5 (4–8) | 10.2 | 9.9 | 12.0 (11.1–12.7) | 2.0 | 5.0 |
| Tutume (189) | 3.0 (2–5) | 10.5 | 13.2 | 11.4 (10.5–12.3) | 4.5 | 8.3 |
| Francistown (102) | 7.0 (4–8) | 6.3 | 6.3 | 11.9 (10.7–12.8) | 1.7 | 1.6 |
| Palapye (91) | 6.0 (3–7) | 5.6 | 6.7 | 12.5 (11.3–13.2) | 0.7 | 1.9 |
| Serowe (79) | 4.0 (4–8) | 5.2 | 4.6 | 12.3 (11.7–13.6) | 0.2 | 2.5 |
| Kweneng West (148) | 6.0 (4–8) | 2.7 | 3.3 | 12.2 (11.8–12.7) | 0.3 | 1.0 |
| Kweneng East (427) | 5.0 (3–8) | 28.8 | 24.1 | 12.2 (11.4–12.9) | 3.9 | 13.1 |
| South East (206) | 4.0 (3–8) | 12.7 | 12.5 | 12.1 (11.3–12.9) | 2.0 | 6.6 |
was affirmed by the clinical outbreak that led to the conclusion by the WHO, during their assessment, that the malaria elimination agenda of Botswana was off course. Kweneng East and South East continue to be hotspots for asymptomatic *P. vivax* infections, which, unfortunately, appear to have spread together with *P. falciparum* into all districts. The presence of significant asymptomatic infections in the population has important implications for strategies and efforts to eliminate malaria. It has been established that ≥75% of *Plasmodium* infections are asymptomatic; however, the strategic approach to interrupt *Plasmodium* transmission largely targets symptomatic infections because data from malaria control programs are accrued from passive rather than active case detection. Asymptomatic infections can be symptomatic during the short term or can remain for long periods before becoming symptomatic. The caveat is that the majority of asymptomatic infections are also submicroscopic. Therefore, only highly sensitive molecular tools can effectively assess their actual extent. It is necessary for malaria elimination programs to change their approach from passive to active case detection with molecular tools, which have the added benefit of being able to detect all *Plasmodium* parasites.

An argument against the detection of asymptomatic infections in NMCPs is based on whether they contribute substantially to transmission. There are transmission hotspots for asymptomatic infections as have been observed for *P. vivax* and *P. falciparum*, thereby affirming that they do contribute to transmission. It has also been observed that some submicroscopic infections may never progress to symptomatic infections and subtly contribute to transmission. There are variations in transmission patterns that are geospatially defined in a country, and these variations need to be understood. According to our report in 2016, Kweneng East, South East, and Tutume were the major hotspots for *P. vivax* infection; however, a new locus of infection for *P. vivax* has emerged in Ngami in the north. Investigations of the Duffy antigen phenotype have been initiated to understand the observed trend.

It is evident that transmission in Okavango has decreased for children younger than 5 years and increased for children 5 years or older. However, it is not clear what the exact reasons are for this observed pattern of infection in this region. Perhaps the persistent efforts by the NMP to mitigate transmission in the district by indoor residual spraying may be a contributory factor. Loci of infections have clearly shifted to the south and southeastern districts, and new strategies are required. The spread of asymptomatic *P. vivax* in the country, including the north, is worrisome because it has significant implications for the elimination agenda because hypnozoites can sustain transmission by serving as infection reservoirs. This also applies to *P. ovale*. The data regarding Duffy negativity in the population are currently unavailable; however, there is the likelihood that some of the *P. vivax* infections will be Duffy-negative, which will sustain the spread. Therefore, the presence of *P. vivax* and *P. ovale* makes it imperative to implement clear plans regarding the use of primaquine in Botswana. Primaquine has a spectrum of antimalarial activities that leads to the radical cure of hypnozoite stages and sterilization of gametocytes in *P. falciparum*. We previously reported that the majority of asymptomatic infections are also Duffy-negative, which will sustain the spread. Therefore, the presence of *P. vivax* and *P. ovale* makes it imperative to implement clear plans regarding the use of primaquine in Botswana.
the G6PD deficiency in Botswana based on the hemizygous male frequency was 2.30% (95% CI, 1.77–2.83), and that the overall frequency of G6PD-deficient genotype A (hemizygote and homozygote genotypes only) was 1.26% (95% CI, 0.86–1.66); these rates should be considered when deciding to implement the use of primaquine in the country.\textsuperscript{41} P. vivax has been labeled as benign, although there is ample evidence to the contrary because of its association with severe malaria.\textsuperscript{42} Perhaps the lack of hyperparasitism observed with P. vivax infections because of the preference for reticulocytes may be a contributing factor.\textsuperscript{43} Recent reports of the presence of P. vivax in bone marrow presented the hematopoietic system as a probable hiding place, in addition to the liver, thereby limiting vascular detection by methods other than PCR in nonendemic areas.\textsuperscript{43,44} What we have observed in Botswana can happen in other African countries that have reported the presence of P. vivax within the population; therefore, serious attention to this matter is required. An important observation is the level of anemia, which was more severe for those younger than 5 years. This observation was related to the district and age, but not the \textit{Plasmodium} infection status; therefore, these anemia cases are more likely to be related to the nutritional status. Nevertheless, we cannot exclude the contribution of existing coinfections. Because anemia can influence infections, and vice versa, particular attention by the NMP is required.\textsuperscript{45}

In conclusion, we have shown that P. vivax is spreading along with \textit{P. falciparum} in the asymptomatic population in Botswana. Local factors that affect transmission dynamics need to be carefully investigated in Botswana and other African countries. To achieve the elimination of malaria, the NMP in Botswana needs to integrate molecular tools in its strategic planning.

Received January 21, 2021. Accepted for publication March 9, 2021.

Acknowledgments: We acknowledge the staff of Botswana NMP who assisted with the field work and the assistance of WWRN in forging the collaboration with A*STAR, Singapore.

Financial support: This work was supported by the Global Health Institute, Merck KGaA, Darmstadt, Germany.

Authors’ addresses: Thato Motshoge and Laurent Rénia, University of Botswana, Gaborone, Botswana, E-mails: motshogethato@yahoo.com and renia_laurent@immunol.a-star.edu.sg. Daniel Hosa Hajayumbo, University of Namibia, School of Medicine, Windhoek, Namibia, E-mail: dhaiyambo@unam.na. Ruth Ayanful-Torgby, Bio-medical and Public Health Research Unit, Council for Scientific and Industrial Research–Water Research Institute, Council Close, Accra, Ghana, E-mail: ruthmine2@gmail.com. Larysa Aleksenko, University of Lund, Lund, Sweden, E-mail: larysa.aleksenko@med.lu.se. Davies Ntebela, National Malaria Program, Ministry of Health and Wellness, Gaborone, Botswana, E-mail: dntebeila834@gmail.com. Benoit Mallaret, Department of Microbiology and Immunology, Yong Loo Lin School of Medicine, National University of Singapore, National University Health System, Singapore, E-mail: benoit.mallaret@nus.edu.sg. Elias Peleowetse, University of Botswana, Gaborone, Botswana, E-mail: peloweem@mopipi.ub.bw. Giacomo Maria Paganotti, Botswana-University of Pennsylvania Partnership, Gaborone, Botswana, Division of Infectious Diseases, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, and Department of Biomedical Sciences, Faculty of Medicine, University of Botswana, Gaborone, Botswana, E-mail: paganottig@bup.org.bw. Isaac K. Quaye, Regent University College of Science and Technology, Dansoman, Accra, Ghana, E-mail: isaac.quaye@regent.edu.gh.

This is an open-access article distributed under the terms of the Creative Commons Attribution (CC-BY) License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Zambezi regions of northern Namibia. Trans R Soc Trop Med Hyg 113: 483–488.

22. Perandin F et al., 2004. Development of a real-time PCR assay for detection of Plasmodium falciparum, Plasmodium vivax, and Plasmodium ovale for routine clinical diagnosis. J Clin Microbiol 42: 1214–1219.

23. Rougemont M, Van Saanen M, Sahl R, Hinrikson HP, Bille J, Jaton K, 2004. Detection of four Plasmodium species in blood from humans by 18S rRNA gene subunit-based and species-specific real-time PCR assays. J Clin Microbiol 42: 5636–5643.

24. Maleret B, Claser C, Ong AS, Suwanarusk R, Sriprawat K, Howland SW, Russell B, Nosten F, Renia L, 2011. A rapid and robust tri-color flow cytometry assay for monitoring malaria parasite development. Sci Rep 1: 118.

25. Huijamo DH, Uusiku P, Mumbengewgi D, Perpina JM, Bock R, Maleret B, Renia L, Greco B, Quaye IK, 2019. Molecular detection of P. vivax and P. ovale foci of infection in asymptomatic and symptomatic children in northern Namibia. PLoS Negl Trop Dis 13: e0007290.

26. Greenwood BM, 1987. Asymptomatic malaria infections—do they matter? Parasitol Today 3: 206–214.

27. Njama-Meya D, Kamya MR, Dorsey G, 2004. Asymptomatic parasitaemia as a risk factor for symptomatic malaria in a cohort of Ugandan children. Trop Med Int Health 9: 862–868.

28. Tran TM, Aghili A, Li S, Ongoiba A, Kayentao K, Doumbo S, Traore B, Crompton PD, 2014. A nested real-time PCR assay for the quantification of Plasmodium falciparum DNA extracted from dried blood spots. Malar J 13: 393-2875-13-393.

29. Douglas AD, Andrews L, Draper SJ, Bojang K, Milligan P, Gilbert SC, Imoukhuede EB, Hill AV, 2011. Substantially reduced prepatent parasite multiplication rates are associated with naturally acquired immunity to Plasmodium falciparum. J Infect Dis 203: 1337–1340.

30. Belizario VY, Saul A, Bustos MD, Lansang MA, Pasay CJ, Gatton M, Salazar NP, 1997. Field epidemiological studies on malaria in a low endemic area in the Philippines. Acta Trop 62: 241–256.

31. Okell LC, Boussema T, Griffin JT, Ouedraogo AL, Ghani AC, Drakeley CJ, 2012. Factors determining the occurrence of submicroscopic malaria infections and their relevance for control. Nat Commun 3: 1237.

32. Bejon P, Andrews L, Hunt-Cooke A, Sanderson F, Gilbert SC, Hill AV, 2006. Thick blood film examination for Plasmodium falciparum malaria has reduced sensitivity and underestimates parasite density. Malar J 5: 104-2875-5-104.

33. Mosha JF et al., 2013. Epidemiology of subpatent Plasmodium falciparum infection: implications for detection of hotspots with imperfect diagnostics. Malar J 12: 221-2875-12-221.

34. Cotter C, Sturrock HJ, Hsiang MS, Liu J, Phillips AA, Hwang J, Gueye CS, Fullman N, Gosling RD, Feachem RG, 2013. The changing epidemiology of malaria elimination: new strategies for new challenges. Lancet 382: 900–911.

35. Cotter C, Sudathip P, Herdiana H, Cao Y, Liu Y, Luo A, Ranasinghe N, Bennett A, Cao J, Gosling RD, 2017. Piloting a programme tool to evaluate malaria case investigation and reactive case detection activities: results from 3 settings in the Asia Pacific. Malar J 16: 347-017-1991-9.

36. Sounounu G, Viriyakosol S, Jarra W, Thaithong S, Brown KN, 1993. Identification of the four human malaria parasite species in field samples by the polymerase chain reaction and detection of a high prevalence of mixed infections. Mol Biochem Parasitol 58: 283–292.

37. Alves FP, Durlacher RR, Menezes MJ, Krieger H, Silva LH, Camargo EP, 2002. High prevalence of asymptomatic Plasmodium vivax and Plasmodium falciparum infections in native Amazonian populations. Am J Trop Med Hyg 66: 641–648.

38. Boussema T et al., 2010. Identification of hot spots of malaria transmission for targeted malaria control. J Infect Dis 201: 1764–1774.

39. Howes RE et al., 2015. Plasmodium vivax transmission in Africa. PLoS Negl Trop Dis 9: e0004222.

40. Recht J, Ashley EA, White NJ, 2018. Use of primaquine and glucose-6-phosphate dehydrogenase deficiency testing: divergent policies and practices in malaria endemic countries. PLoS Negl Trop Dis 12: e0006230.

41. Motshoge T et al., 2018. Prevalence of G6PD deficiency and associated haematological parameters in children from Botswana. Infect Genet Evol 63: 73–78.

42. Naing C, Whittaker MA, Nyunt Wai V, Mak JW, 2014. Is Plasmodium vivax malaria a severe malaria? A systematic review and meta-analysis. PLoS Negl Trop Dis 8: e3071.

43. Silva-Filho JL, Lacerda MVG, Recker M, Wassmer SC, Marti M, Costa FM, 2020. Plasmodium vivax in hematopoietic niches: hidden and dangerous. Trends Parasitol 36: 447–458.

44. Obaldia N, 3rd et al., 2018. Bone marrow is a major parasite reservoir in Plasmodium vivax infection. MBio 9. doi: 10.1128/mBio.00625-18.

45. White NJ, 2018. Anaemia and malaria. Malar J 17: 371-018-2509-9.